Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
FAQ
- What is Corvus Pharmaceuticals's D&A?
- Corvus Pharmaceuticals (CRVS) reported D&A of $29K in Q1 2026.
- How has Corvus Pharmaceuticals's D&A changed year-over-year?
- Corvus Pharmaceuticals's D&A increased by 31.8% year-over-year, from $22K to $29K.
- What is the long-term trend for Corvus Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's D&A has grown at a -30.9% compound annual growth rate (CAGR), from $460K to $105K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Corvus Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude